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ABSTRACT: The Escherichia coli DNA repair enzyme MutY plays an important role in the recognition
and repair of 7,8-dihydro-8-oxo-2′-deoxyguanosine:2′-deoxyadenosine (OG:A) mismatches in DNA
[Michaels et al. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 7022-7025]. MutY prevents DNA mutations
resulting from the misincorporation of A opposite OG by using N-glycosylase activity to remove the
adenine base. An interesting feature of MutY is that it contains a [4Fe-4S]2+ cluster that has been shown
to play an important role in substrate recognition [Porello, S. L., Cannon, M. J., David, S. S. (1998)
Biochemistry 37, 6465-6475]. Herein, we have used site-directed mutagenesis to individually replace
the cysteine ligands to the [4Fe-4S]2+ cluster of E. coli MutY with serine, histidine, and alanine. The
extent to which the various mutations reduce the levels of protein overexpression suggests that coordination
of the [4Fe-4S]2+ cluster provides stability to MutY in vivo. The ability of the mutated enzymes to bind
to a substrate analogue DNA duplex and their in vivo activity were evaluated. Remarkably, the effects
are both substitution and position dependent. For example, replacement of cysteine 199 with histidine
provides a mutated enzyme that is expressed at high levels and exhibits DNA binding and in vivo activity
similar to the WT enzyme. These results suggest that histidine coordination to the iron-sulfur cluster
may be accommodated at this position in MutY. In contrast, replacement of cysteine 192 with histidine
results in less efficient DNA binding and in vivo activity compared to the WT enzyme without affecting
levels of overexpression. The results from the site-directed mutagenesis suggest that the structural properties
of the iron-sulfur cluster coordination domain are important for both substrate DNA recognition and the
in vivo activity of MutY.
DNA is subject to a variety of chemical modifications
resulting from hydrolytic reactions, the action of alkylating
agents, radiation, and oxidative stress (1). Moreover, errors
in DNA replication can lead to base pair mismatches resulting
in permanent alterations of the genome’s informational
content. Fortunately, elaborate repair pathways exist in all
organisms to protect them from the potential deleterious and
mutagenic effects of DNA damage and mismatches (2).
There are an increasing number of examples illustrating the
importance of DNA repair in the prevention of diseases such
as cancer (2). For example, a direct link between defective
DNA mismatch repair and hereditary nonpolyposis colon
cancer has been established (3, 4).
The base excision repair (BER)1 pathway is primarily
responsible for the repair of damage to heterocyclic DNA
bases (5, 6). DNA glycosylases are the marquee players in
the BER pathway by virtue of their ability to recognize
damaged or mismatched bases and catalyze N-glycosidic
bond cleavage to effect base release. Subsequent action of
apurinic apyrimidinic (AP) endonucleases, DNA polymerase,
and DNA ligase restores the correct, undamaged nucleotide
(6). In Escherichia coli, two BER glycosylases, MutM (also
called FPG) and MutY, play a coordinated role in preventing
mutations caused by oxidative damage to guanine in DNA
(Figure 1) (7). MutM removes the oxidatively damaged
residue, 7,8-dihydro-8-oxo-2′-deoxyguanosine (OG), from
DNA (8). If the OG lesion escapes MutM, miscoding by
OG during DNA replication may result in the formation of
an OG:A mismatch (9, 10). If the OG:A base pair is left
unrepaired, replication of the “A” strand secures a permanent
G-to-T transversion mutation. MutY circumvents such DNA
mutations by removing adenine bases from OG:A base pairs
(11, 12). Restoration of the G:C base pair is achieved by
the action of an AP endonuclease, DNA polymerase, DNA
ligase, and MutM (13). MutY is also active in the removal
of adenine from G:A base pairs within DNA (14); however,
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the rate of adenine removal from OG:A substrates is
significantly faster than from G:A substrates (15).
MutY belongs to a superfamily of BER enzymes which
recognize a wide variety of damaged or inappropriate bases.
Structural studies of two superfamily members, E. coli
endonuclease III (endo III, Figure 2) and AlkA, indicate that
these two enzymes have a similar overall three-dimensional
fold and contain a helix-hairpin-helix (HhH) motif which
is highly conserved within the superfamily (16-19). E. coli
MutY exhibits particularly high sequence homology to endo
III. Both enzymes are involved in the repair of oxidative
DNA damage; however, in contrast to MutY, endo III
displays glycosylase activity for DNA containing damaged
pyrimidines such as ring-saturated and ring-fragmented
thymine derivatives (20-22). A unique feature of both E.
coli MutY and E. coli endo III is that they have been shown
to contain a [4Fe-4S]2+ cluster (23, 24). The spacing of
cysteine ligands in endo III is unique from that found in other
[4Fe-4S] proteins (25), indicating that this enzyme is
representative of a distinct class of Fe-S proteins. A number
of glycosylase enzymes in the BER superfamily, including
Micrococcus luteus UV endonuclease and a G:T-specific
thymine glycosylase from Methanobacterium thermofor-
micicum, contain the same conserved pattern of cysteine
residue spacing, suggesting that they also contain a similarly
coordinated [4Fe-4S]2+ cluster (6).
The crystal structure of E. coli endo III (17, 26) (Figure
2) shows that four cysteines, arranged with contiguous
spacing (Cys187-X6-Cys194-X2-Cys197-X5-Cys203) near
the C-terminus, coordinate the cluster to form a distinct metal
cluster coordination domain. On the basis of limited protease
digestion (27, 28) and sequence homology to endo III (29),
MutY may be divided into two domains: an N-terminal
domain (Met 1-Lys 225) that possesses high sequence
homology to endo III (66.3% similar and 23.8% identical in
a 181 amino acid span) and a C-terminal extension domain
(Gln 226-Val 350). On the basis of the homology to endo
III, cysteine residues 192, 199, 202, and 208 were proposed
to be the ligands to the [4Fe-4S] cluster in MutY (29). The
recently reported X-ray structure of MutY’s N-terminal
domain confirms this cluster coordination (30).
The presence of a [4Fe-4S]2+ cluster in several DNA
repair enzymes is unusual since iron-sulfur clusters are more
commonly found in proteins involved in electron transfer
reactions (31). However, many nonredox roles for Fe-S
clusters have been uncovered, suggesting that they are
versatile cofactors (32, 33). In endo III, the observation that
the cluster is resistant to oxidation or reduction has been
used as an argument against its involvement in electron
transfer (23). The X-ray crystal structure of endo III (26)
reveals the presence of common amino acids used in DNA
phosphate recognition (lysine and arginine) within a solvent-
exposed loop between the first two cysteine ligands to the
Fe-S cluster. This region, termed the iron-sulfur cluster
loop (FCL) motif, appears nicely poised for interactions with
DNA (17). Indeed, replacement of a lysine residue by
glutamic acid in the FCL of endo III resulted in a >100-
fold increase of Km (17). These results led to the conclusion
that the cluster in endo III may act indirectly in DNA
recognition by stabilizing the binding motif or more directly
as a structural motif for interaction with DNA (17). Recent
studies from our laboratory involving the refolding of MutY
showed that, in vitro, assembly of the cluster is not required
for initiation of global folding of the enzyme, and the cluster
does not contribute to the overall thermal stability of the
protein (24). However, the presence of the cluster is required
for MutY’s ability to bind to substrate DNA. Not surpris-
ingly, efficient substrate recognition is needed to support
MutY’s adenine glycosylase activity, and therefore MutY
lacking the cluster is also completely inactive in vitro.
Cysteine is the most common ligand to iron-sulfur
clusters in proteins. However, chemical models have also
indicated that a wide variety of ligands including phenolates,
alkoxides, carboxylates, and imidazolates can coordinate iron
FIGURE 1: Repair system for 7,8-dihydro-8-oxo-2′-deoxyguanosine involving MutM (FPG) and MutY. Adapted from ref 6 and 7.
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in iron-sulfur compounds (34-37). In contrast, the natural
occurrence of [4Fe-4S] clusters coordinated by amino acids
other than cysteine is exceedingly rare. Documentated cases
include DesulfoVibrio gigas Ni-Fe hydrogenase (3 Cys, 1
His) (38), the Fe-only hydrogenase from Clostridium pas-
teurianum (3 Cys, 1 His) (39), and a ferredoxin from the
hyperthermophile Pyrococcus furiosus (3 Cys, 1 Asp) (40).
Several modified Fe-S proteins have been produced using
site-directed mutagenesis that contain a noncysteinyl ligand
coordinated to an iron-sulfur cluster (41). Indeed, the
substitution of cysteine by serine in iron-sulfur proteins has
been commonly used for the identification of ligands (41,
42). In some cases, a modified [4Fe-4S] cluster utilizing
coordination by the introduced ligand has been produced (43,
44). However, due to the fact that protein-bound iron-sulfur
clusters usually provide stability to the protein, noncysteinyl
ligands may significantly destabilize the iron-sulfur cluster.
Typically, mutagenesis of the cysteine ligands results in loss
of the cluster or modification of its nuclearity ([3Fe-4S])
(44-46). Furthermore, the less stable nature of noncysteinyl
coordination often makes isolation of these modified proteins
difficult (41). This has been illustrated in Chromatium
Vinosum HiPIP where individual Cys-to-Ser substitution of
the four cysteines coordinating the [4Fe-4S] cluster allowed
for isolation and purification of only the C77S mutated
enzyme (47).
In the present work, site-directed mutagenesis has been
used to individually alter MutY’s [4Fe-4S] cluster cysteine
ligands to serine, histidine, or alanine. The effects of these
modifications on the stability of the enzyme, its ability to
bind DNA, and its in vivo activity have been determined.
These results suggest that the [4Fe-4S] cluster provides
stability to the MutY protein in vivo. Furthermore, alteration
of the [4Fe-4S] cluster coordination is found to affect both
the DNA binding properties and in vivo activity of MutY.
Interestingly, serine, histidine, and alanine replacements of
the cysteine ligands produce contrasting effects on the
stability and activity of the protein, suggesting that histidine
and serine in some positions may serve as ligands to the
iron-sulfur cluster in MutY.
MATERIALS AND METHODS
General Methods, Bacterial Strains, Materials, and In-
strumentation. Common E. coli strains JM101 and JM109
were used in this work (48). In JM101 mutY - the
chromosomal copy of the mutY gene was disrupted by
transduction of mutY::mini-tn 10 into JM101. Strain CC104
is a derivative of the strain P90C containing a lacZ mutation
at residue 461 of â-galactosidase (49). E. coli strain GT100
is ara, ¢(gpt-lac)5, rpsL, [F′lacIqL8, proA+B+] (7). These
strains are more fully described by Miller (48). The E. coli
strains CC104 mutM::mini-kan mutY::mini-tn 10, GT100
mutY::mini-tn 10 mutM-, and JM101 mutY::mini-tn 10 were
generous gifts from Dr. M. L. Michaels (Amgen). The
plasmid containing the mutY gene, pKKYEco, was kindly
provided by Drs. M. L. Michaels and J. H. Miller. All
common DNA manipulations were performed using standard
protocols (50). Enzymes were purchased from Boehringer
Mannheim. All 2′-cyanoethyl phosphoramidites were pur-
chased from ABI, except the 7,8-dihydro-8-oxo-2′-deoxy-
guanosine phosphoramidite which was purchased from Glen
Research. The 2′-deoxyformycin A phosphoramidite was
synthesized as described previously (51). DNA oligonucle-
otides were synthesized by standard phosphoramidite chem-
istry on an Applied Biosystems DNA synthesizer (model
392) as per the manufacturer’s protocol. Oligonucleotides
for MutY assays were purified and handled as described
previously (52). The oligonucleotides used for PCR reactions
were purified using oligonucleotide purification cartridges
(Perkin-Elmer). All buffers and other reagents used were
purchased from Fisher, Sigma, or USB. 5′-End-labeling was
performed with T4 polynucleotide kinase purchased from
New England Biolabs in the presence of ç-32P-ATP from
Amersham Life Sciences. Labeled oligonucleotides were
FIGURE 2: Three-dimensional structure of E. coli endonuclease III from the X-ray crystallographic data (17). The structure is shown in a
ribbon representation, with the [4Fe-4S] cluster shown using a space-filling representation. The helix-hairpin-helix motif and the iron-
sulfur coordination domain (containing all four cysteines ligating the cluster) are shaded in black. The implicated active site lies within the
cleft between these two sequence motifs. The figure was generated using the Brookhaven PDB file ABK2.
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purified using the Nensorb 20 purification system (DuPont-
NEN). UV-visible absorption spectroscopy was performed
on a Hewlett-Packard 8452A diode array spectrophotometer.
Storage phosphor autoradiography was performed using a
Molecular Dynamics STORM 840 Phosphorimager.
Site-Directed Mutagenesis. Site-directed mutagenesis was
performed by a modification (53, 54) of a method (55) which
uses two successive rounds of polymerase chain reaction
(PCR) to first introduce the desired mutation and then
amplify the entire gene. The pKKYEco plasmid, in which a
2 kb DNA fragment containing the E. coli MutY gene was
cloned between the EcoRI (5′-end) and PstI (3′-end) restric-
tion sites of the expression vector pKK223-3 (Pharmacia),
was used to prepare a new plasmid, pKKYEco2. This new
construction, used as template for PCR reactions, differs from
the parent plasmid (pKKYEco) in that the PstI site is located
directly after the Stop codon of mutY. The appropriate
oligonucleotide primers (Supporting Information) were used
to introduce the desired mutation.
The PCR reactions were performed in a GeneAmp PCR
system 2400 (Perkin-Elmer) in a 100 íL reaction volume.
For the first PCR, 10 ng of template, 75 pmol of primer 01
(5′-ctg aaa tga gct gtt gac-3′) and the primer containing the
desired mutation (Supporting Information), 20 nmol of each
dNTP, and 2.5 units of Pwo DNA polymerase were used in
a buffer containing 10 íL of 10X Pwo buffer. The settings
of the thermocycler were 94 °C for 1 min, 45 °C for 1 min,
and 72 °C for 1 min, over 30 cycles. The second PCR
reaction is performed under the same conditions as the first
except that 75 pmol of primer 03 (5′-ggc tga aaa tct tct ctc-
3′) and 10 íL of the first PCR reaction are used as the
primers. The PCR products were analyzed on a high melting
point agarose gel and purified by phenol extraction. The
product of the second PCR was digested by PstI and EcoRI
enzymes and purified on a low melting point agarose gel.
The resulting fragment of DNA was ligated with T4 DNA
ligase between the EcoRI and PstI sites of the pKK223-3
plasmid. The modified plasmid was transformed into E. coli
strain JM109 and plated on LB agar plates containing 100
mg/L ampicillin. Subsequently, an inoculated 5 mL LB
culture containing 100 mg/L ampicillin was grown, and the
plasmid was purified from the cells with the WizardPlus
MiniPrep kit (Promega). The sequence was confirmed using
automated fluorescent sequencing (56) on an ABI Prism 377
automated DNA sequencer (PE Applied Biosystems) at the
Huntsman Cancer Institute sequencing facility (University
of Utah).
Protein Labeling by 35S-Cysteine. E. coli strain JM101
mutY::mini-tn 10 harboring the pKKYEco2 plasmid contain-
ing mutY or a modified mutY gene was grown in LB medium
containing 100 mg/L ampicillin and 15 mg/L tetracycline.
When the measured optical density at 600 nm reached 0.9,
1 mL of culture was induced with 1 mM isopropyl â-D
thiogalactoside (IPTG). After 15 min of induction, ap-
proximately 5 íCi of 35S-cysteine (Amersham) was added,
and the cells were grown for three additional hours. The cells
were concentrated by centrifugation, and the protein products
were resolved by electrophoresis on a 12% SDS polyacryl-
amide gel. The dried gel was exposed to a storage phosphor
screen for a minimum of 8 h, and the resulting storage
phosphor autoradiogram was quantified using ImageQuaNT
software (Molecular Dynamics).
Preparation of Cellular Lysates for DNA Binding Assays.
E. coli strain JM101 mutY::mini-tn 10 harboring the ap-
propriate plasmid (pKK223-3, pKKYEco2, or a modified
pKKYEco2) was grown overnight in LB medium containing
100 mg/L ampicillin and 15 mg/L tetracycline. Overnight
cultures (1.5 mL) were used to inoculate 150 mL of LB
containing ampicillin and tetracycline. The culture was grown
at 37 °C until an optical density at 600 nm of approximately
0.9 was reached. At this point, the culture was induced with
1 mM IPTG and grown at 37 °C for three additional hours.
Cells were concentrated by centrifugation and resuspended
in 1 mL of buffer A (50 mM Tris-HCl, pH 8.0, 2 mM EDTA,
5 mM DTT, 250 mM NaCl, 5% glycerol). The resuspended
cells were sonicated and then centrifuged at 14 000 rpm at
4 °C for 15 min. The cellular lysate was recovered as the
supernatant and the protein concentration determined by
Bradford assay (Biorad) (57).
Gel Retardation Assay with Cellular Lysates. Gel retarda-
tion assays (52, 58) were performed using the following
duplex: d(5′-CGATCATGGAGCCAC(OG)AGCTCCCGT-
TACAG-3′)¥d(3′-GCTAGTACCTCGGTGFTCGAGGGCA-
ATGTC-5′). The OG-strand was 5′-32P-end labeled prior to
annealing to the complementary strand. Reactions (20 íL)
containing 500 pM duplex, 20 mM Tris-HCl (pH 7.5), 100
mM NaCl, 1 mM EDTA, 1 mM DTT, 10% glycerol, and
0.1 mg/mL BSA were incubated at 37 °C with various
amounts of cellular lysate. A range of cellular lysate
concentrations was used by dilution with a dilution buffer
(20 mM Tris-HCl, pH 7.5, 10 mM EDTA, 20% glycerol).
After 30 min of incubation, nondenaturing loading dye was
added, and the samples were electrophoresed on a 6%
nondenaturing polyacrylamide gel (17 cm  14 cm  0.3
cm) with 0.5X TBE buffer at 200 V for 15 min and at
100 V for 2 h at 4 °C. The dried gel was exposed to a
storage phosphor screen for 8-10 h. The storage phosphor
autoradiogram was quantified using ImageQuaNT software
(MD).
The percent bound DNA versus log[protein] was plotted,
and the concentration required to give 50% bound DNA (C50)
was determined. At least three separate measurements using
freshly prepared cellular lysates from independent cultures
were averaged for the reported C50 values.
In ViVo ActiVity. The pKK223-3 or pKKYEco2 plasmid
containing the mutY (or a mutated mutY gene) was trans-
formed into E. coli strain CC104 (12, 49) mutM::mini-kan
mutY::mini-tn 10 (7). A minimum of 16 independent
overnight cultures were grown in LB medium containing 100
mg/L ampicillin and 50 mg/L kanamycin. To determine the
number of viable cells, a 107-fold dilution was plated on LB
agar plates containing ampicillin (100 mg/L) and kanamycin
(50 mg/L). A variable volume was also plated on two
different types of agar plates to test for mutator frequency
(48). One set of LB plates containing ampicillin (100 mg/
L), kanamycin (50 mg/L), and rifampicin (100 mg/L) was
used to measure rifampicin revertants (Rifr). The other set
consisted of minimal lactose plates containing ampicillin (100
mg/L) and kanamycin (50 mg/L) to determine Lac+ rever-
tants. After overnight incubation at 30 °C, Rifr colonies were
counted. Lac+ colonies were counted after 2 days of
incubation at 30 °C. The experiments with GT100 mutM-
mutY::mini-tn 10 were similar except that the plates did not
contain kanamycin and only the Rifr colonies were measured.
7000 Biochemistry, Vol. 38, No. 22, 1999 Golinelli et al.
MutY Homology Model. The sequences of E. coli MutY
and endo III were aligned as reported previously by Michaels
et al. (29) using the Homology module of Insight II (MSI,
v. 97.0) on a Silicon Graphics O2 workstation. Coordinates
for the endo III X-ray crystal structure (17) were obtained
from the Brookhaven Protein Data Bank, file accession
number 2ABK. Using these coordinates, homologous resi-
dues of MutY were mapped onto the structure of endo III.
Loop regions were generated for nonhomologous sections
of MutY and spliced between homologous portions. The
[4Fe-4S]2+ coordinates for endo III were used to map the
cluster to the model of MutY. A “bump” check routine was
used to verify that no areas of significant van der Waals
overlap among side chains were present. Hydrophobicity
analysis of the MutY model was accomplished using the
Engleman-Steitz algorithm.
RESULTS
Choice of Mutations. In E. coli endo III, cysteines 187,
194, 197, and 203 are ligands of the [4Fe-4S] cluster (23,
26). On the basis of the sequence alignments between E.
coli endo III and E. coli MutY, cysteines 192, 199, 202, and
208 were proposed to be the ligands of the cluster in MutY
(29). Recently, this proposal was confirmed by the X-ray
structural characterization of the catalytic domain of MutY
(30). To probe the role of the iron-sulfur cluster in MutY,
we individually altered each of the four cysteine ligands to
histidine, serine, and alanine. The replacement of a single
cysteine with alanine removes a possible ligand to the cluster
at this position. However, cysteine replacement by serine or
histidine will alter the type of ligand available for coordina-
tion to the cluster.
LeVels of OVerexpression of Mutated Enzymes. In numer-
ous examples, replacement of cysteine ligands to an iron-
sulfur cluster using site-directed mutagenesis has resulted
in a significant reduction of the amount of protein produced
(41). In cases where the WT gene is well-expressed, such a
decrease in the amount of polypeptide chain is unlikely to
result from a modification of a transcription-translation
series of events. Rather, the lower level of expression of the
modified gene is more likely related to instability of the
mutated protein. This is particularly true with mutations that
affect assembly of metal sites since the correct insertion of
an Fe-S cluster is often a determining factor in the folding
of an Fe-S protein (41). If the mutated enzyme does not
retain the cluster or contains a malformed cluster, it may be
improperly folded and therefore more susceptible to degrada-
tion by cellular proteases.
To study the involvement of each of these four cysteines
in the in vivo stabilization of the protein, the amount of
polypeptide chain produced during overexpression of each
modified MutY protein was determined. The different
mutated plasmids were prepared using a PCR-based method
(Supporting Information), and the enzymes were overex-
pressed in E. coli under conditions similar to the WT enzyme.
Proteins produced during the overexpression were radioac-
tively labeled by incorporation of 35S-cysteine after induction
with IPTG. The proteins in the crude extracts were then
analyzed by SDS-PAGE, and the amount of MutY polypep-
tide chain was quantified using storage phosphor autorad-
iography. To eliminate interference with the WT enzyme,
the overexpression of the mutated enzymes was performed
in an E. coli strain lacking the chromosomal copy of WT
MutY. Using this procedure, the levels of overexpression of
each mutated form relative to the WT enzyme were
determined (Table 1).
Individual replacements of the cysteines at positions 192,
199, 202, and 208 by serine dramatically lowers the
overexpression of the enzyme. Indeed, the maximum over-
expression observed for the serine substitutions (C192S,
C199S)2,3 is less than 15% of WT MutY. The overexpression
of the mutated forms containing histidine is significantly
higher on average. This is especially striking for the C192H
and C199H forms, which are overexpressed at levels similar
to the WT enzyme. In contrast, when one of these two
cysteines (192, 199) is replaced by an alanine, no polypeptide
chain was detected in the 35S-labeling experiment. The
observation that individual alterations at all four cysteine
positions affects overexpression levels is consistent with their
involvement in the coordination of the cluster in the WT
form of MutY. Furthermore, these results suggest that
coordination of the cluster is involved in stabilizing MutY
in vivo.
The effects of these mutations are also highly dependent
on the position of the modified residue. The instability of
the C192A and C199A enzymes indicates that a ligand at
these positions stabilizes the protein. The removal of a ligand
may produce a modified protein with a [3Fe-4S] cluster, a
[4Fe-4S] cluster with an alternative ligand, or no cluster. It
is possible that none of these forms are able to sufficiently
sustain MutY’s proper folding to prevent its degradation by
cellular proteases. The higher overexpression of the histidine
and serine mutated forms at positions 192 and 199 compared
to the analogous alanine mutations suggests that histidine
and serine may coordinate the cluster. In contrast, the
mutation of cysteine 202 or 208 to serine or histidine
dramatically reduces the amount of protein that is observed.
This indicates that the presence of cysteine residues at
positions 202 and 208 is required for efficient protein
overexpression. However, histidine replacement is again
favored over serine as in positions 192 and 199, since
quantifiable amounts of the C202H (5%) and C208H (20%)
forms relative to the WT form are observed, while no
polypeptide chain could be observed for the corresponding
serine mutated enzymes.
It is anticipated that the low overexpression of many of
the mutated enzymes will severely hamper their purification.
Specifically, alterations or loss of the cluster could occur
during the process of purification. Indeed, attempts to purify
some of the mutated forms resulted in loss of the cluster.
Thus, to obtain information on all of the mutated forms, even
those that are highly destabilized, we have taken advantage
of the ability of MutY present in cellular lysates to bind with
high affinity to a substrate analogue. Moreover, the activity
of the mutated forms can be evaluated in vivo using MutY’s
ability to prevent G:C f T:A transversion mutations.
DNA Binding Experiments with Cellular Lysates. The WT
form of MutY specifically recognizes OG:A mismatches and
2 An example of the abbreviation used to represent mutated MutY
enzymes is as follows: C192S, cysteine 192 replaced by a serine.
3 The X-ray crystal structure of the catalytic domain of MutY was
published (30) during the time that this manuscript was undergoing
review; however, the crystallographic coordinates are not yet available.
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catalyzes the hydrolysis of the N-glycosidic bond of the
misincorporated 2′-deoxyadenosine (13). Previous work in
our laboratory (52) has shown that an OG:F (F ) 2′-
deoxyformycin A) mismatch within a DNA duplex is
recognized with high affinity (Kd  500 pM) by MutY.
However, the nucleotide F contains a C-glycosidic linkage
which provides resistance to the glycosylase activity of
MutY. Thus, oligonucleotide duplexes containing an OG:F
mismatch are effective substrate analogues that allow an
evaluation of specific binding by MutY without the com-
plications of the enzymatic reaction.
A nondenaturing gel retardation method (58) was used to
monitor specific complex formation between the OG:F
duplex and enzyme present in cellular lysates prepared from
the overexpression of MutY (WT or mutated form) in a mutY
- E. coli strain. To reduce protein degradation, cellular lysates
were prepared immediately prior to performing the gel
retardation assay. Using cellular lysates from the overex-
pression of WT MutY, only one retarded band was observed
(Figure 3B). This band co-migrates with the retarded band
observed when purified WT MutY is used (Figure 3C) and
is representative of the MutY/DNA substrate analogue
complex (52). In the analogous experiment with cells
transformed with the plasmid pKK223-3, in which no copy
of mutY is present, no retarded band at the position
corresponding to the MutY-DNA complex was observed
(Figure 3A); however, when an extremely high concentration
of crude extract was used (Figure 3A, lane 1), a more highly
retarded band was observed with a relative mobility consis-
tent with results obtained using purified E. coli MutM (data
not shown). It is likely that this band comes from MutM
present in the cellular lysates, since the chromosomal mutM
gene is not disrupted in this E. coli strain. In experiments
using cellular lysates containing overexpressed MutY, this
band was not observed (Figure 3B) as a consequence of
MutY’s higher affinity for the OG:F duplex and higher
concentration relative to MutM. Importantly, these results
show that we can specifically monitor binding of MutY to
the OG:F duplex in cellular lysates.
The formation of the MutY-DNA complex was monitored
as a function of the total protein concentration in the cellular
lysates to determine a C50 value which represents the amount
of total protein (in ng) necessary to obtain 50% bound DNA
(Figure 3D). When WT MutY is overexpressed, a C50 of
115 ( 30 ng was determined. Among all the different
mutated forms, high affinity binding was only observed with
the C199S and C199H forms (Table 1). Indeed, the C50 for
the cellular lysates containing C199H (180 ( 100 ng) and
C199S (490 ( 300 ng) are in the same range as the value
obtained with the extracts containing WT MutY. The average
C50 value for C199S is slightly higher than for the WT or
the C199H form, possibly a consequence of the lower
overexpression of this mutated form (Table 1). Surprisingly,
in similar experiments using the corresponding serine and
histidine mutations at position 192, significant binding to
the substrate analogue duplex is not observed even though
the overexpression of these forms is similar to those at
position 199.
Table 1: Stability, DNA Binding, and in Vivo Activity Data Obtained on the Cluster Ligand Mutated Forms of MutY
in vivo activity (CC104)b in vivo activity (GT100)b
protein
relative
overexpression (%)a
maximal %
bound DNA
C50 (ng) in
cell extracts
no. of colonies
(Rifr, Lac+) % activityc
no. of colonies
(Rifr) % activity
control 0d 0 1780 ( 580 0 980 ( 160 0
2814 ( 880
WT 100 90 115 ( 30 7 ( 5 100 2 ( 1 100
24 ( 19
C192S 12 0 21 ( 6 100 9 ( 2 99
29 ( 12
C192H 78 9 435 ( 120 78 973 ( 205 0
607 ( 151
C192A 0d 9 29 ( 11 98 255 ( 74 76
126 ( 108
C199S 12 75 490 ( 300 19 ( 9 100 3 ( 1 100
9 ( 4
C199H 99 85 180 ( 100 10 ( 5 100 1 ( 1 100
14 ( 1
C199A 0d 5 1 ( 1 100 16 ( 3 98
11 ( 2
C192A-C199A 0d 0 1654 ( 242 4 1011 ( 310 0
3174 ( 846
C202S 0d 0 18 ( 2 99 704 ( 74 28
60 ( 28
C202H 5 0 327 ( 110 83 762 ( 175 23
870 ( 170
C208S 0d 5 10 ( 3 100 740 ( 56 24
34 ( 18
C208H 20 10 34 ( 22 100 608 ( 213 38
22 ( 5
a This is expressed as a percentage compared to the amount of the WT form. The amount of polypeptide chain from a given experiment is
determined by the percent of MutY polypeptide chain compared to the rest of the proteins produced during the overexpression. The error in these
values is estimated to be 10-20%. b An in vivo activity of 100% is given to the cells transformed by pKKYEco2 (WT form of MutY) and 0% for
those transformed by the plasmid lacking the mutY gene (pKK223-3). The values for Rifr and Lac+ reversions were determined by averaging at
least three separate experiments. Both CC104 and GT100 strains used in these experiments are mutY- mutM-. c This represents an average of the
percent activity obtained from Rifr and Lac+ assay. d A percent polypeptide chain of “0” is reported when no band corresponding to MutY is
detected on the SDS polyacrylamide gel using 35S-Cys labeling of the overexpressed proteins.
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Using extremely high concentrations of cellular lysates, a
small amount of MutY-DNA complex (<10%) with the
C192H, C192A, C199A, C208S, and C208H forms was
observed. The C192H form is overexpressed to high levels,
and therefore the low amount of binding suggests that
alteration of the cysteine ligand to histidine at this position
severely compromises the DNA binding affinity of the
enzyme. In contrast, the C192A, C199A, C208S, and C208H
forms were overexpressed at low levels. Indeed, the 35S-
labeled polypeptide chain for the C192A, C199A, and C208S
forms could not be detected by SDS-PAGE. The observa-
tion of a DNA-MutY complex suggests that a small amount
of these mutated forms are present in the cellular extracts.
Interestingly, with the C192A-C199A form, no polypeptide
chain was observed by SDS-PAGE and no DNA binding
could be observed in the gel retardation assay even at
extremely high concentrations of cellular extract (Table 1).
The double mutation ensures that the polypeptide chain
cannot coordinate an iron-sulfur cluster like the WT enzyme.
Taken together, these results suggest that the small amount
of the C192A, C199A, C208S, C208H enzymes that was
present contains a cluster of some form (a [3Fe-4S] or a
[4Fe-4S]) in order to account for the ability to bind the
substrate analogue OG:F duplex.
In ViVo ActiVity. Miller et al. have shown that in the
absence of MutY, cells exhibit an increase in G:C f T:A
transversion mutations (12). In the E. coli strain CC104, the
lacZ gene is inactivated by mutation of Glu 461 (codon
GAG) to Gln (codon GCG), and the cells can revert back to
the Lac+ phenotype only via a G:C f T:A transversion (49,
59). As a consequence, the absence of MutY activity results
in a high level of reversion to the Lac+ phenotype, enabling
the E. coli to grow on lactose as the only carbon source. In
addition, the in vivo mutation frequency can also be
determined by using the ability of rifampicin to block
bacterial RNA polymerases (60). In the absence of MutY
activity, a high level of DNA mutations creates modifications
in the rifampicin binding site of RNA polymerase, thus
providing the E. coli with resistance to rifampicin. Miller et
al. have also shown that if only the chromosomal mutY gene
is disrupted, the mutation rate, as judged by both the
generation of colonies able to grow on rifampicin containing
plates (rifampicin revertants, Rifr) and the rate of G:C f
T:A tranversions in a Lac+ reversion assay, is low due to
the presence of MutM (7, 12, 61). Indeed, when a CC104
strain where mutY and mutM are disrupted was used, the
mutation rate was significantly higher (approximately 1790
Rifr and 2814 Lac+ colonies for 108 cells compared to 21
and 59, respectively, in the CC104 mutY- strain, Table 1).
Expression of WT MutY by transformation of the CC104
mutY- mutM- E. coli strain with pKKYEco2 significantly
decreased the rate of G:C f T:A transversion mutations (7
Rifr and 26 Lac+ colonies for 108 cells). Thus, the presence
of MutY in these cells was able to significantly reduce the
appearance of mutations. It is important to note that in these
experiments, MutY was constitutively expressed due to the
fact that the E. coli strain CC104 is lacI- and consequently
the tac promotor of pKKYEco2 was not repressed.
The in vivo activity of the different mutated forms of
MutY is shown in Figure 4 and Table 1. Surprisingly, all of
the serine and the two single alanine mutated forms (C192A,
C199A) exhibited an in vivo activity comparable to the WT
form, even though minimal overexpression was observed.
In contrast, the mutated forms containing histidine exhibited
a lower average in vivo activity, despite displaying more
efficient overexpression than the serine counterparts. This
is most striking for the C192H form which has a relatively
low in vivo activity compared to the other mutated forms.
The in vivo activity is completely abolished only with the
C192A-C199A form. In this case, overexpression and DNA
binding were not observed. The high level of in vivo activity
for the C192A, C199A, C202S, and C208S forms suggests
that only a small amount of active enzyme is needed for
complete complementation and that expression of the WT
enzyme provides much more enzyme than is needed. This
FIGURE 3: Storage phosphor autoradiogram of gel retardation assay
to detect binding of MutY in cellular lysates to a substrate analogue
30-mer duplex containing a central OG:F base pair. Lanes in panel
A contain cellular extract from E. coli JM101 mutY::mini-tet strain
transformed by pKK223-3 (expression plasmid lacking mutY gene).
Lanes in panel B contain crude extract from the same strain
containing the plasmid pKKYEco2 (contains WT MutY). Lanes
in panel C contain purified WT MutY. The amount of crude extract
(in ng total protein) used in panels A and B is 75, 38, 19, 9, 5, and
2 ng (left to right). Panel D is a representative gel retardation assay
used to quantitate the DNA binding of WT MutY in cellular lysates.
The amount of cellular lysate (in ng total protein) used was as
follows: 2500 (lane 1), 1250 (lane 2), 625 (lane 3), 312 (lane 4),
156 (lane 5), 78 (lane 6), 39 (lane 7), 20 (lane 8), 10 (lane 9), 5
(lane 10), 2 (lane 11), 1 (lane 12). The OG-strand of the OG:F
duplex (500 pM) was 5′-end labeled with 32P. The C50 obtained
for this particular experiment was 134 ng. Average values from at
least three separate determinations are listed in Table 1.
FIGURE 4: Number of Rifr and Lac+ colonies obtained with the in
vivo experiment performed with E. coli strain CC104 mutY::mini-
tn 10 mutM::mini-kan transformed with pKKYEco2 plasmid (WT
or modified mutY genes). The results are normalized with a value
of 100 attributed to the result with E. coli transformed with
pKK223-3 plasmid.
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hypothesis is further supported by the fact that the reversion
frequency of the E. coli strains CC104 and CC104 mutY-
transformed with pKKYEco are similar despite the larger
cellular concentration of MutY in the latter (7). This feature
of the assay may be masking some of the differences in the
activity of the mutated forms.
To differentiate between the active forms, similar experi-
ments were performed using the lacIq E. coli strain GT100
(7), in which the tac promoter of pKK223-3 is strongly
repressed in the absence of IPTG. This strain does not have
the mutation in the lacZ gene and therefore only Rifr can be
used to determine the mutation frequency. Nonetheless, our
results in CC104 (Table 1) indicate that the variation in G:C
f T:A transversions (Lac+ assay ) is proportional to the
variation in overall mutation rate (Rifr assay). Using this
strain, full complementation was observed with E. coli
expressing the WT enzyme; however, differences in the
mutation rates were observed for mutated forms with low
overexpression (Figure 5 and Table 1). For example, the
histidine and serine mutated forms at positions 202 and 208
are significantly less active than the WT, consistent with the
lower levels of expression of these mutated forms. However,
even using this lacIq strain, a small amount of protein is
required for full complementation as illustrated by the fact
that C199A was able to provide complete complementation
even though its presence was not detected in the overex-
pression experiments. This indicates that the low in vivo
activity of some mutated forms may not only be a conse-
quence of low amounts of the protein but also be due to an
intrinsic lower activity. Indeed, an interesting trend is
observed at position 192, where relative levels of overex-
pression (C192H > C192S > C192A) do not correlate with
the relative activity (C192S > C192A > C192H). This
suggests that the low in vivo activity of C192H is a
consequence of modification of the properties of the protein
resulting from the mutation, rather than the amount of protein
present.
DISCUSSION
On the basis of the homology to E. coli endo III, the
cysteines in E. coli MutY at positions 192, 199, 202, and
208 were proposed to be the ligands to the [4Fe-4S] cluster
(29), and this has been recently confirmed by the X-ray
structural characterization of the catalytic domain of E. coli
MutY (30). In the present work, our results demonstrate that
substitution of one of these four cysteines by serine severely
compromises the expression of the MutY polypeptide chain.
This is most likely due to a reduction in the amount of
completely folded protein due to cluster destabilization. This
assertion is further supported by the observed differences in
overexpression when these cysteines are substituted by a
different type of potential ligand (histidine) or with an amino
acid containing a side chain that cannot coordinate a metal
ion (alanine). At all four positions, the relative overexpression
indicates that replacing the cysteine ligands with histidine
is considerably less destabilizing than the analogous serine
substitution. Substitution of cysteine by alanine at positions
192 and 199 does not provide a ligand to the cluster, and no
polypeptide chain is observed with either alanine substitution.
Thus, these results suggest that both serine and histidine may
serve as ligands to the cluster to account for the higher
overexpression. Taken together, these results are consistent
with a requirement for the presence of the [4Fe-4S] cluster
in order to establish a stable, folded conformation of MutY
in vivo.
Recent work in our laboratory (24) has shown that in vitro
MutY can be refolded with and without reassembly of the
[4Fe-4S] cluster as judged by the lack of major differences
in the CD spectrum. These results suggest that [4Fe-4S]
cluster assembly is not required in initiating enzyme folding
or in stabilizing MutY’s overall structure in vitro. Such
results may seem to be contradictory to those reported herein
based on the overexpression of cluster ligand mutated forms.
However, this likely reflects differences in the processes of
MutY folding in vitro and in vivo. Indeed, the assembly and
insertion of Fe-S clusters into proteins in vivo is not well-
understood. In vivo, the absence or alteration of the cluster
may not affect the overall structure, but may result in a local
structural modification that increases the protein’s suscep-
tibility to proteolytic degradation. Furthermore, the in vitro
refolding was monitored by CD spectroscopy which is not
a sensitive technique for detecting minor changes in protein
structure. Consequently, the resistance to proteolytic degra-
dation may be a more sensitive assay for the complete folding
of MutY. Previous work with native MutY has shown that
limited proteolytic digestion provides two stable fragments
(27, 28) and therefore, it will be interesting to determine if
MutY enzyme forms lacking the cluster are more susceptible
to proteolysis in vitro.
Significantly, though MutY can be refolded without
assembly of the [4Fe-4S] cluster, this apo-enzyme form does
not exhibit adenine glycosylase activity or the ability to bind
to a substrate analogue DNA duplex (24). On the basis of
these previous results, it is likely that a mutated MutY
enzyme that does not contain the iron-sulfur cluster will
be unable to bind the substrate analogue OG:F duplex. Thus,
the observation of in vivo activity and DNA binding with
some of the mutated enzymes is suggestive of the presence
of an Fe-S cluster in these modified enzymes. Most notably,
the in vivo activity and DNA binding properties of the
C199H and C199S enzymes are comparable to those of the
WT enzyme, which suggests that these forms contain the
[4Fe-4S] cluster.
The C199A form exhibits activity in the in vivo assay,
suggesting that a small amount of cluster-containing protein
is present in the cells. However, the replacement of cysteine
with alanine requires a major modification of the cluster
FIGURE 5: Number of Rifr and Lac+ colonies obtained with the in
vivo experiment performed with E. coli strain GT100 mutY::mini-
tn 10 mutM::mini-kan containing the pKKYEco2 plasmid (WT or
modified mutY gene). The results are normalized with a value of
100 attributed to the result with E. coli transformed by the
corresponding plasmid (pKK223-3) lacking mutY.
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nuclearity or coordination. In this case, the absence of
measurable overexpression and minimal DNA binding
indicates that this form is highly unstable. This is in direct
contrast with the results obtained with the C199H and C199S
enzymes. Indeed, the results with C199H and C199S are
consistent with a significantly different coordination which
provides stability when the cells are lysed for the DNA
binding experiments. This suggests that the [4Fe-4S] cluster
present is likely coordinated by the new ligand that has been
introduced. Histidine coordination to a [4Fe-4S] cluster has
been observed in the crystallographic characterization of D.
gigas Ni-Fe hydrogenase (38) and C. pasterianum Fe-
hydrogenase (39). Serine coordination to a [4Fe-4S] cluster
has been implicated in the C184S mutated form of the â
subunit of E. coli nitrate reductase (62) and in the C148S
and C151S forms of the FrdB subunit of E. coli fumarate
reductase (44). In addition, NMR studies of the C77S
mutated form of C. Vinosum HiPIP has confirmed serinate
coordination to the [4Fe-4S] center (47, 63).
Based on the differences in side chain length, the serine
mutation might be expected to minimally perturb the overall
structure compared to the incorporation of histidine. How-
ever, the high levels of expression for the C199H and C192H
forms suggest that histidine coordination may be more easily
accommodated by MutY’s [4Fe-4S] cluster. In inorganic
model compounds, Fe(II/III)-OR distances (1.9 Å) are
considerably shorter than the corresponding Fe(II/III)-SR
distances (2.3 Å) (36, 64). In the case of histidine, the side
chain is longer than that in cysteine; however, Fe-N(His)
distances are expected to be significantly shorter (ap-
proximately 2.0-2.1 Å) than Fe-S(Cys) distances (36, 65).
In examples with serine incorporation into Fe-S proteins,
the observed Fe-O(Ser) distances are variable (1.9-2.3 Å),
suggesting that the distance adopted in proteins is dependent
on the protein matrix (66, 67). Thus, incorporation of both
serine and histidine may involve movement of the side chain
or polypeptide chain to accommodate cluster coordination
or the coordination of the cluster may not be optimal. Both
of these conditions may affect the stability as well as activity
of the mutated enzyme.
By taking advantage of the high sequence and structural
homology of MutY and endo III around the [4Fe-4S]
cluster, a model of this region in MutY was generated (Figure
6).3 In endo III, the hydrophilic FCL motif (Thr 186 to Cys
194) has been implicated in DNA binding (17). The
corresponding FCL region in MutY (Ile 191 to Cys 199) is
also highly hydrophilic, containing positively charged resi-
dues commonly used in DNA recognition (Arg 194, Lys 196,
Lys 198) (Figure 6). The ability to accommodate substitutions
of Cys 192 and Cys 199 in MutY is likely a consequence of
the flexibility and hydrophilicity of the polypeptide loop
between these residues. In contrast, Cys 202 and Cys 208
are located in a hydrophobic portion of the protein, and
mutations in hydrophobic segments are generally more
destabilizing than in hydrophilic regions (68). The differences
in stability of mutated forms depending on the position of
the modified cysteine may also be a consequence of a
difference in the function of these four cysteines in stabilizing
the structure of the protein. In endo III, the four correspond-
ing cysteines participate in hydrogen bonding with the amide
backbone or an arginine side chain. The loss of similar types
of hydrogen bonding at the corresponding cysteines in MutY
by the mutations may destabilize the protein. Moreover, in
MutY, cysteines 202 and 208 are located near the C-terminal
extension domain, and replacement of these cysteines may
increase the flexibility of the C-terminal end of the protein,
consequently decreasing its stability.
The most dramatic effects on the DNA binding and in
vivo activity are observed in the substitutions at position 192.
The replacement of cysteine with histidine and serine at
position 192 results in similar levels of overexpressed protein
as the corresponding replacements at position 199. This
suggests that these forms may contain a [4Fe-4S] cluster
coordinated by the introduced amino acid to account for the
increased stability of these forms relative to the C192A form.
However, the C192H and C192S proteins do not exhibit high
affinity for the OG:F substrate analogue duplex as was
observed with the corresponding C199S/H enzymes. In the
in vivo assay using the GT100 strain, both C192S and C192A
exhibit near WT activity, while C192H has no activity. The
inactivity in the in vivo assay and the inability of C192H
enzyme to bind the OG:F duplex may be due to the lack of
the [4Fe-4S] cluster. However, this explanation seems
inconsistent with its high relative overexpression. A more
likely explanation is that the reduced DNA binding ability
of C192H is a direct result of histidine coordination which
may be unfavorable to the activity relative to the cluster
coordination present in the C192S and C192A enzymes.
Unusual coordination of the [4Fe-4S] cluster may alter
the redox properties of the cluster (35, 47, 44, 63), and this
could account for the lower activity of the C192H enzyme.
However, the inability to reduce or oxidize the [4Fe-4S]2+
cluster of endo III suggests that this class of DNA repair
FIGURE 6: Homology model of P26 domain of MutY based on
endo III crystal structure (17) showing the [4Fe-4S] cluster
coordination domain containing the four cysteine ligands (192, 199,
202, and 208). The polypeptide backbone is represented by a ribbon
with the side chains of the cysteine ligands shown. The [4Fe-4S]
cluster is shown in a ball-and-stick representation. The polypeptide
chain has been shaded to indicate hydrophobicity versus hydro-
philicity. Darkly shaded regions are hydrophobic, while lightly
colored regions are hydrophilic. Neutral regions are shaded in gray.
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enzymes is not involved in a redox reaction (23). A more
likely explanation for the reduced activity of the C192H form
is that this mutation has resulted in a local modification of
the protein’s conformation that reduces efficient substrate
recognition. In the endo III structure (17, 26), the Sç atom
of Cys 187 (equivalent to 192 in MutY) forms a hydrogen
bond with the NŁ2 atom of Arg 147 (equivalent to Arg 147
in MutY). Assuming that similar interactions may be present
in MutY, mutation of Cys 192 to histidine would result in
loss of this hydrogen bond and potentially modify the
conformation of MutY’s FCL. Conformational changes in
the polypeptide chain proximal to position 192 may also be
required in order to accommodate the histidine ligation.
Alterations of the conformation of MutY’s FCL, which
contains residues that may be involved in DNA recognition,
may explain the decreased ability of the C192H form to
interact with DNA. This suggests that the [4Fe-4S]2+ cluster
in MutY may provide the scaffolding for proper positioning
of the amino acids for interactions with DNA in a manner
analogous to that previously proposed for endo III (17).
To establish whether histidine or serine is coordinated to
the [4Fe-4S] cluster, purification of the C192H, C192S,
C199H, and C199S MutY enzymes is in progress. If
purification of the holoproteins is possible, spectroscopic
studies will be useful in determining the coordination of the
[4Fe-4S] cluster and the effect of such atypical coordination
on the properties of a [4Fe-4S] cluster. If unique spectro-
scopic signatures of these modified MutY forms are identi-
fied, this may also provide spectroscopic handles for
determining the effects of substrate and substrate analogue
binding on the properties of MutY’s [4Fe-4S] coordination
domain. A thorough characterization of the DNA binding
and enzymatic properties of some of these modified forms
is also in progress. This will provide further insight into the
specific roles the [4Fe-4S] cluster and the FCL motif play
in detecting OG:A mismatches within DNA.
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